Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss

By Reuters News


Overview

  • US biotech firm's fiscal Q4 revenue missed analyst expectations

  • Net loss widened to $23.7 mln from $18.7 mln

  • Company cut workforce by about one-third in September to boost efficiency and extend cash runway


Outlook

  • Company expects topline data from LOTUS pediatric RSV trial in 1Q 2027

  • Topline data from RESOLVE adult RSV trial expected in 2027

  • Company expects cash and marketable securities to fund operations into fiscal 2029


Result Drivers

  • ROYALTY REVENUE DECLINE - Co said Q4 revenue decrease was due to lower royalties from AbbVie's sales of MAVYRET/MAVIRET

  • HIGHER R&D SPENDING - Co said Q4 R&D expenses rose due to increased clinical trial costs for RSV programs, driven by RESOLVE and LOTUS studies


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Miss

$12.87 mln

$14.20 mln (3 Analysts)

Q4 Loss Per Share

$0.81

Q4 Net Loss

$23.72 mln

Q4 Operating Expenses

$34.91 mln

Q4 Operating Income

-$22.04 mln

Q4 Pretax Loss

$23.75 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 82% above its November 13 closing price of $10.99


Reuters Recommended Reads

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.